Bristol-Myers Squibb

Bristol-Myers CEO: We’re ‘one step closer to creating that great company’ with Celgene
Bristol-Myers CEO: We’re ‘one step closer to creating that great company’ with Celgene
CNBC
M&A
Bristol-Myers Squibb
Celgene
Pharma CEOs
Giovanni Caforio
Flag link:
The Bristol-Celgene merger is approved. Here are 8 challenges ahead
The Bristol-Celgene merger is approved. Here are 8 challenges ahead
Stat
Bristol-Myers Squibb
Celgene
M&A
Flag link:
Nobel laureate behind Bristol's I-O superstar Opdivo demands a bigger cut
Nobel laureate behind Bristol's I-O superstar Opdivo demands a bigger cut
Fierce Pharma
Opdivo
Bristol-Myers Squibb
Ono Pharmaceutical
R&D
Flag link:
Bristol-Myers details its failure on Checkmate 451, highlighting a bleak future for their checkpoint combo
Bristol-Myers details its failure on Checkmate 451, highlighting a bleak future for their checkpoint combo
Endpoints
Bristol-Myers Squibb
Opdivo
Yervoy
small cell lung cancer
Flag link:
The top 15 pharma companies by 2018 revenue
The top 15 pharma companies by 2018 revenue
Fierce Pharma
JNJ
Roche
Pfizer
Novartis
Merck
GSK
Sanofi
AbbVie
Bayer
Eli Lilly
Amgen
Bristol-Myers Squibb
Gilead Sciences
Teva Pharmaceutical
AstraZeneca
Flag link:
Big Pharma come together for better drug side effect detection
Big Pharma come together for better drug side effect detection
Pharma Times
side effects
adverse events
Pfizer
Roche
Takeda
Eli Lilly
Bristol-Myers Squibb
Gilead Sciences
Alexion
Celgene
International Working Group on Signal Detection and Management in Pharmacovigilance
pharmacovigilance
Flag link:
Bristol-Myers' big Celgene buyout showers $187M-plus on Morgan Stanley
Bristol-Myers' big Celgene buyout showers $187M-plus on Morgan Stanley
Endpoints
Bristol-Myers Squibb
Celgene
Morgan Stanley
M&A
Flag link:
Despite research boom, few immunotherapy studies targeting pancreatic cancer
Despite research boom, few immunotherapy studies targeting pancreatic cancer
Biopharma Dive
pancreatic cancer
cancer immunotherapy
AACR
Bristol-Myers Squibb
Merck
Apexigen
Flag link:
Bristol-Myers Squibb's Opdivo-Yervoy duo provokes response in rare tumors
Bristol-Myers Squibb's Opdivo-Yervoy duo provokes response in rare tumors
Fierce Pharma
Bristol-Myers Squibb
Opdivo
Yervoy
neuroendocrine tumors
Flag link:
After winning key support for Celgene buyout, Bristol-Myers CEO Caforio emerges as clear likely winner in looming shareholder vote
After winning key support for Celgene buyout, Bristol-Myers CEO Caforio emerges as clear likely winner in looming shareholder vote
Endpoints
Bristol-Myers Squibb
Celgene
M&A
Starboard
Giovanni Caforio
Flag link:
Bristol-Myers Squibb and Concerto HealthAI Sign Cancer Real World Data Agreement
Bristol-Myers Squibb and Concerto HealthAI Sign Cancer Real World Data Agreement
BioSpace
Bristol-Myers Squibb
Concerto HealthAI
oncology
real world data
real world evidence
artificial intelligence
Flag link:
Bristol-Myers scores a critical endorsement for its embattled Celgene merger
Bristol-Myers scores a critical endorsement for its embattled Celgene merger
Stat
Bristol-Myers Squibb
Celgene
M&A
Flag link:
Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal
Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal
TheStreet.com
SEC
FTC
M&A
Bristol-Myers Squibb
Celgene
Flag link:
Could proxy advisors sway investors to vote ‘no’ on BMS-Celgene merger?
Could proxy advisors sway investors to vote ‘no’ on BMS-Celgene merger?
Fierce Pharma
Bristol-Myers Squibb
Celgene
investors
M&A
Flag link:
Bristol-Myers and Starboard Value spar over $74B Celgene buyout as shareholder vote looms
Bristol-Myers and Starboard Value spar over $74B Celgene buyout as shareholder vote looms
Endpoints
Bristol-Myers Squibb
Starboard
Celgene
M&A
Flag link:
Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?
Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?
Motley Fool
M&A
Bristol-Myers Squibb
Celgene
Flag link:
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
Investors Business Daily
Celgene
Novartis
ozanimod
MS
multiple sclerosis
patents
Bristol-Myers Squibb
M&A
Flag link:
Bristol-Myers CEO Caforio wants M&A dissidents to know there's been no 'high level' overtures about buying the company since '17
Bristol-Myers CEO Caforio wants M&A dissidents to know there's been no 'high level' overtures about buying the company since '17
Endpoints
Bristol-Myers Squibb
Celgene
Giovanni Caforio
M&A
Flag link:
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Celgene Submits MS Drug for Approval in Europe, FDA Filing on Track
Xconomy
Celgene
Bristol-Myers Squibb
Europe
FDA
M&A
MS
multiple sclerosis
ozanimod
Flag link:
Does Bristol-Myers have a plan B if activists scuttle its Celgene buy?
Does Bristol-Myers have a plan B if activists scuttle its Celgene buy?
Fierce Pharma
Bristol-Myers Squibb
Celgene
M&A
Flag link:

Pages